Search

Your search keyword '"Razavi, Pedram"' showing total 723 results

Search Constraints

Start Over You searched for: Author "Razavi, Pedram" Remove constraint Author: "Razavi, Pedram"
723 results on '"Razavi, Pedram"'

Search Results

1. $\tau$-bench: A Benchmark for Tool-Agent-User Interaction in Real-World Domains

2. Automated real-world data integration improves cancer outcome prediction

3. DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism

5. COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease.

6. Assessing Unique Risk Factors for COVID-19 Complications Among Cancer Patients: A Multi-ethnic Cohort Study.

7. Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer

8. Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study

9. Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion

10. Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer

14. Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a CCC19 registry analysisImpact of B-cell malignancy therapy on COVID-19 outcomes

15. Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer

16. Morphological and genomic characteristics of breast cancers occurring in individuals with Lynch Syndrome

17. Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study

18. Nonlobular Invasive Breast Carcinomas with Biallelic Pathogenic CDH1 Somatic Alterations: A Histologic, Immunophenotypic, and Genomic Characterization

20. A machine learning model that classifies breast cancer pathologic complete response on MRI post-neoadjuvant chemotherapy.

21. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

22. Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study

24. Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2- metastatic breast cancer: A machine learning approach.

26. Genomic biomarkers of CNS-specific outcomes in patients with breast cancer brain metastases.

27. Overall survival analysis of first line CDK4/6 inhibitors in a large real-world cohort of patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer.

29. Effect of strain and diameter on electronic and charge transport properties of indium arsenide nanowires

30. Influence of surface stoichiometry and quantum confinement on the electronic structure of small diameter InxGa1-xAs nanowires

31. Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA

35. Liquid biopsies for residual disease and recurrence

36. Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions

38. Multimodal histopathologic models stratify hormone receptor-positive early breast cancer

39. Homologous recombination deficiency and tumor suppressor heterozygosity mediate resistance to front-line therapy in breast cancer

40. Optimal Systemic Treatment and Real-World Clinical Application of Ctdna in Patients with Metastatic Her2-Mutant Lung Cancer

42. Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS

44. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients

46. Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

47. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants

49. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors

50. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer

Catalog

Books, media, physical & digital resources